Hide Message

Updating the Resource Centre Digital Platform

The Business & Human Rights Resource Centre is at a critical point in its development. Our digital platform is home to a wealth of information on business and human rights, but hasn’t had a visual refresh for a number of years.

We will soon be updating the site to improve its usability and better serve the thousands of people that use our site to support their work.

Please take an advance peek at our new look, and let us know what you think!

Thank you,
Alex Guy, Digital Officer

Find Out More Hide Message

Big Pharma ups its game in providing drugs to people in poor countries

Author: Sarah Boseley, Guardian [UK], Published on: 28 November 2012

Pharmaceutical companies are doing more to help people in developing countries obtain the drugs they need, according to the latest Access to Medicines Index... GlaxoSmithKline...continues to top the league table...Johnson & Johnson and...Sanofi are now close behind. The index...has become an authoritative guide... Drug companies are scored on a range of measures, from their willingness to discount prices in poor countries, to research on neglected diseases of poor people to lobbying, transparency and conduct in clinical trials...But there are concerns that Big Pharma is not demonstrating real influence over the private contractors...[that] carry out drug trials in the developing world. [other companies in index in order of ranking: Merck & Co., Gilead Sciences, Novo Nordisk, Novartis, Merck KGaA, Bayer, Roche, Pfizer, Bristol-Myers Squibb, Abbott Laboratories, Eli Lilly, Eisai, AstraZeneca, Boehringer-Ingelheim, Takeda Pharmaceutical, Daiichi Sanyko, Astellas Pharma]

Read the full post here

Related companies: Abbott Laboratories AstraZeneca Bayer Boehringer Ingelheim Bristol-Myers Squibb Daiichi Sankyo Eisai Eli Lilly Gilead Sciences Johnson & Johnson Merck Novo Group Novo Nordisk (part of Novo Group) Pfizer Roche Sanofi Takeda Pharmaceutical